Sobieski MM - Search Results

1

Agents that stabilize mutated von Hippel-Lindau (VHL) protein: results of a high-throughput screen to identify compounds that modulate VHL proteostasis.

Ding Z, German P, Bai S, Feng Z, Gao M, Si W, Sobieski MM, Stephan CC, Mills GB, Jonasch E. Ding Z, et al. Among authors: sobieski mm. J Biomol Screen. 2012 Jun;17(5):572-80. doi: 10.1177/1087057112436557. Epub 2012 Feb 21. J Biomol Screen. 2012. PMID: 22357874 Free PMC article.

2

A high content clonogenic survival drug screen identifies mek inhibitors as potent radiation sensitizers for KRAS mutant non-small-cell lung cancer.

Lin SH, Zhang J, Giri U, Stephan C, Sobieski M, Zhong L, Mason KA, Molkentine J, Thames HD, Yoo SS, Heymach JV. Lin SH, et al. J Thorac Oncol. 2014 Jul;9(7):965-973. doi: 10.1097/JTO.0000000000000199. J Thorac Oncol. 2014. PMID: 24922006 Free PMC article.

3

Spatial mapping of the biologic effectiveness of scanned particle beams: towards biologically optimized particle therapy.

Guan F, Bronk L, Titt U, Lin SH, Mirkovic D, Kerr MD, Zhu XR, Dinh J, Sobieski M, Stephan C, Peeler CR, Taleei R, Mohan R, Grosshans DR. Guan F, et al. Sci Rep. 2015 May 18;5:9850. doi: 10.1038/srep09850. Sci Rep. 2015. PMID: 25984967 Free PMC article.

4

Xenotransplantation of pediatric low grade gliomas confirms the enrichment of BRAF V600E mutation and preservation of CDKN2A deletion in a novel orthotopic xenograft mouse model of progressive pleomorphic xanthoastrocytoma.

Kogiso M, Qi L, Lindsay H, Huang Y, Zhao X, Liu Z, Braun FK, Du Y, Zhang H, Bae G, Zhao S, Injac SG, Sobieski M, Brunell D, Mehta V, Tran D, Murray J, Baxter PA, Yuan XJ, Su JM, Adesina A, Perlaky L, Chintagumpala M, Parsons DW, Lau CC, Stephan CC, Lu X, Li XN. Kogiso M, et al. Oncotarget. 2017 Sep 8;8(50):87455-87471. doi: 10.18632/oncotarget.20713. eCollection 2017 Oct 20. Oncotarget. 2017. PMID: 29152094 Free PMC article.

5

GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.

Vijay GV, Zhao N, Den Hollander P, Toneff MJ, Joseph R, Pietila M, Taube JH, Sarkar TR, Ramirez-Pena E, Werden SJ, Shariati M, Gao R, Sobieski M, Stephan CC, Sphyris N, Miura N, Davies P, Chang JT, Soundararajan R, Rosen JM, Mani SA. Vijay GV, et al. Breast Cancer Res. 2019 Mar 7;21(1):37. doi: 10.1186/s13058-019-1125-0. Breast Cancer Res. 2019. PMID: 30845991 Free PMC article.

6

Exploring the advantages of intensity-modulated proton therapy: experimental validation of biological effects using two different beam intensity-modulation patterns.

Ma D, Bronk L, Kerr M, Sobieski M, Chen M, Geng C, Yiu J, Wang X, Sahoo N, Cao W, Zhang X, Stephan C, Mohan R, Grosshans DR, Guan F. Ma D, et al. Sci Rep. 2020 Feb 21;10(1):3199. doi: 10.1038/s41598-020-60246-5. Sci Rep. 2020. PMID: 32081928 Free PMC article.

7

Author Correction: Exploring the advantages of intensity-modulated proton therapy: experimental validation of biological effects using two different beam intensity-modulation patterns.

Ma D, Bronk L, Kerr M, Sobieski M, Chen M, Geng C, Yiu J, Wang X, Sahoo N, Cao W, Zhang X, Stephan C, Mohan R, Grosshans DR, Guan F. Ma D, et al. Sci Rep. 2020 Oct 30;10(1):19101. doi: 10.1038/s41598-020-75965-y. Sci Rep. 2020. PMID: 33127998 Free PMC article.

8

Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer.

Inoue A, Robinson FS, Minelli R, Tomihara H, Rizi BS, Rose JL, Kodama T, Srinivasan S, Harris AL, Zuniga AM, Mullinax RA, Ma X, Seth S, Daniele JR, Peoples MD, Loponte S, Akdemir KC, Khor TO, Feng N, Roszik J, Sobieski MM, Brunell D, Stephan C, Giuliani V, Deem AK, Shingu T, Deribe YL, Menter DG, Heffernan TP, Viale A, Bristow CA, Kopetz S, Draetta GF, Genovese G, Carugo A. Inoue A, et al. Among authors: sobieski mm. Gastroenterology. 2021 Jul;161(1):196-210. doi: 10.1053/j.gastro.2021.03.022. Epub 2021 Mar 19. Gastroenterology. 2021. PMID: 33745946 Free PMC article.

9

Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models.

Handley KF, Rodriguez-Aguayo C, Ma S, Stur E, Joseph R, Bayraktar E, Dasari SK, Nguyen N, Powell RT, Sobieski M, Ivan C, Kim M, Umamaheswaran S, Glassman D, Wen Y, Amero P, Stephan C, Coleman RL, Landesman Y, Westin SN, Ram PT, Sood AK. Handley KF, et al. Mol Cancer Ther. 2021 Dec;20(12):2352-2361. doi: 10.1158/1535-7163.MCT-21-0370. Epub 2021 Sep 28. Mol Cancer Ther. 2021. PMID: 34583979 Free PMC article.

10

Combined inhibition of HMGCoA reductase and mitochondrial complex I induces tumor regression of BRAF inhibitor-resistant melanomas.

de Groot E, Varghese S, Tan L, Knighton B, Sobieski M, Nguyen N, Park YS, Powell R, Lorenzi PL, Zheng B, Stephan C, Gopal YNV. de Groot E, et al. Cancer Metab. 2022 Feb 22;10(1):6. doi: 10.1186/s40170-022-00281-0. Cancer Metab. 2022. PMID: 35193687 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

15 results

Search Page